Litfulo capsule for people with severe alopecia areata in routine care

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a post‑marketing observational study that follows patients prescribed Litfulo (ritlecitinib tosylate) during routine clinical care to collect safety and outcome data. No experimental procedures are required beyond standard treatment; clinicians will record adverse events, serious adverse events, adverse events of special interest (including serious infections, opportunistic infections, herpes zoster, and malignancy), and any unexpected reactions. Eligible participants are adolescents (12 years and older) and adults with severe alopecia areata who are starting Litfulo per its approved indication and who provide informed consent. Data will be collected at the Pfizer clinical site in Seoul and analyzed to identify real‑world safety signals and treatment patterns.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Patients with severe alopecia areata who have been determined to start treatment with Litfulo Capsule according to the approved indications of the medicinal product Treatment of severe alopecia areata in adults and adolescents 12 years or older Evidence of a personally signed and dated informed consent document indicating that the patient or their parent(s)/legal guardian, if applicable, have been informed of all pertinent aspects of the study

Where it's running

• Pfizer
  Seoul, South Korea Recruiting

Study contacts

• Study coordinator: Pfizer CT.gov Call Center
• Email: ClinicalTrials.gov_Inquiries@pfizer.com
• Phone: 1-800-718-1021

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Upadacitinib for Severe Alopecia Areata in Children

  This study tests whether upadacitinib can safely help children with severe alopecia areata grow back hair, compared with placebo.

  Recruiting at 14 sites Phase 3 AbbVie · Los Angeles, California and 13 other locations · NCT07772492

• Safety and body handling of IBI3013 after single and multiple doses in healthy adults and men with active non-segmental vitiligo or severe alopecia areata

  This trial tests whether IBI3013 is safe and how the body processes it in healthy adults and in men with active non-segmental vitiligo or severe alopecia areata.

  Recruiting Phase 1 Innovent Biologics (Suzhou) Co. Ltd. · Shanghai, Shanghai Municipality · NCT07554222

• Long-term ritlecitinib treatment for children with severe alopecia areata

  This study will give ritlecitinib to children who completed earlier Pfizer pediatric ritlecitinib studies to see if long-term treatment is safe and helps maintain or improve hair regrowth.

  Recruiting at 56 sites Phase 3 Pfizer · Irvine, California and 66 other locations · NCT07029828

• Which works better for patchy hair loss: steroid injections or microneedling with steroid cream?

  This trial tests whether injecting triamcinolone into the skin or using microneedling with topical triamcinolone helps people with alopecia areata regrow hair more effectively.

  Recruiting Phase 4 Dow University of Health Sciences · Karachi, Sindh · NCT07926711

• Red Ultraviolet Hair Imaging and Hair Growth in Alopecia Areata

  This observational study checks if red fluorescence seen with UV hair imaging relates to disease features and how well hair regrows after standard intralesional corticosteroid treatment in adults with limited plaque-type alopecia areata.

  Recruiting Istanbul Training and Research Hospital · Istanbul · NCT07803874

• VC005 tablets in teens with severe alopecia areata

  This Phase 1 study tests VC005 tablets in adolescents with severe alopecia areata to see how the drug behaves in the body, whether it is safe, and if there are signs of benefit.

  Recruiting Phase 1 Jiangsu vcare pharmaceutical technology co., LTD · Beijing, Beijing Municipality · NCT07762443

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.